关键信息
-
基因名
Claudin-9/CLDN9
-
简介
Claudin-9/CLDN9 protein-VLP plays a crucial role in tight junctions by eliminating intercellular spaces through calcium-independent cell adhesion activity. In microbial infections, it acts as a receptor that facilitates the entry of hepatitis C virus (HCV) into hepatocytes. Claudin-9/CLDN9 Protein-Nanodisc, Human (Biotinylated, HEK293, His, Avi) is the recombinant human-derived Claudin-9/CLDN9 protein, expressed by HEK293, with C-His and C-Avi labeled tag.
- 应用
-
别名
Claudin-9; CLD9
-
种属
Human
-
表达系统
HEK293
-
标签
C-His;Avi
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O95484
-
表达区间
M1-T184
-
蛋白长度
Partial
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Claudin-9 (CLDN9) is a member of the claudin family of proteins, which are essential components of tight junctions in epithelial and endothelial cells. These proteins play a critical role in maintaining the integrity of cell layers, regulating paracellular permeability, and contributing to barrier functions in various tissues. Recent studies have highlighted the significance of CLDN9 in various physiological and pathological processes, including cell adhesion, migration, and signal transduction. Its expression has been linked to certain cancers, where altered tight junction dynamics may facilitate tumor progression and metastasis. Research focusing on CLDN9 recombinant proteins has garnered interest as these proteins offer a valuable tool for elucidating the molecular mechanisms underlying tight junction modulation. By producing and characterizing CLDN9 in a recombinant system, scientists aim to better understand its structural properties, functional interactions, and potential as a therapeutic target. Moreover, recombinant CLDN9 can be used in high-throughput screening assays for drug discovery and to assess the impact of various compounds on tight junction integrity. Understanding the role of CLDN9 in cellular contexts may pave the way for novel therapeutic strategies in diseases characterized by compromised epithelial barriers, such as inflammatory disorders and cancer. Overall, research on CLDN9 recombinant proteins is vital for both basic biology and clinical applications, highlighting the need for continued investigation into their function and potential roles in health and disease.
